Cargando…
Decreased FOXP3+ and GARP+ Tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer
Neoadjuvant chemotherapy (NACT) has been an increasingly used therapeutic strategy to improve the outcome of advanced gastric cancer (GC) over the past few decades. Lymphocytic infiltration has been reported to be associated with response to NACT, but the immune cell subpopulation and its prognosis...
Autores principales: | Li, Kai, Chen, Fuchao, Xie, Huijuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913533/ https://www.ncbi.nlm.nih.gov/pubmed/27366089 http://dx.doi.org/10.2147/OTT.S101884 |
Ejemplares similares
-
Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP
por: Elkord, Eyad, et al.
Publicado: (2015) -
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients
por: Samid, May Abd Al, et al.
Publicado: (2016) -
FOXP3 and GARP (LRRC32): the master and its minion
por: Probst-Kepper, Michael, et al.
Publicado: (2010) -
GARP: a key receptor controlling FOXP3 in human regulatory T cells
por: Probst-Kepper, M, et al.
Publicado: (2009) -
Human LAP(+)GARP(+)FOXP3(+) regulatory T cells attenuate xenogeneic graft versus host disease
por: Wang, Huihui, et al.
Publicado: (2019)